.png){kind=icon}
.png){kind=icon}
Return
Evolution of the Use of Circulating DNA as a Biomarker in Neoadjuvant Therapy of Breast Cancer
.png){kind=icon}
OA
AI
J
F
A
M
DOI：10.3390/curroncol33080450.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Management of locally advanced breast cancer necessitates multimodal treatment, including neoadjuvant chemotherapy (NACT). Current predictive and prognostic markers often fall short in the neoadjuvant context. We have evaluated past and current applications of cfDNA and/or ctDNA in the neoadjuvant setting. The original studies have focused on cfDNA as an indicator of response, particularly cfDNA integrity, whereby higher integrity levels correlate with better prognosis. Similarly, levels of epigenetic methylation of ctDNA were significantly decreased in treatment responders. The use of ctDNA positivity and its persistence were associated with shorter disease-free and overall survival. Finally, approaches based on longitudinal evaluation of ctDNA have demonstrated clinical utility for early identification of patients at high risk for post-operative recurrence. While most reports include assessment of prognosis and detection of recurrence, there is only limited utility in the prediction of outcomes of NACT.
Keywords:
breast cancer
cfDNA
ctDNA
neoadjuvant chemotherapy
prediction
prognosis
Journal
C
IF:
3.4
Papers:
780
Citations:
0
Organization
Cited Papers